{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:37:16Z","timestamp":1771504636153,"version":"3.50.1"},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To assess clinical utility of measurements of C-reactive protein (CRP) versus Westergren erythrocyte sedimentation rate (ESR) in evaluating patients with rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Data from 3 randomized clinical trials of golimumab involving 1247 patients with RA in which ESR and CRP were obtained at baseline and Week 24, along with standard measures of clinical disease activity [swollen and tender joint counts, global disease activity assessment, composite Disease Activity Scores (DAS) and Clinical Disease Activity Index (CDAI)], were utilized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result.<\/jats:title><jats:p>Both ESR and CRP were significant predictors of swollen joint count (p &lt; 0.001 for each). Only 4.5% of patients with no swollen joints had elevated CRP and normal ESR, but 15.2% had elevated ESR and normal CRP. ESR and CRP correlated significantly (Pearson r = 0.59, p &lt; 0.001) with each other. DAS-ESR and DAS-CRP were highly correlated (r = 0.96, p &lt; 0.001) with each other, although DAS-ESR values were slightly lower than the DAS-CRP values at the upper end of the range (DAS &gt; 8). Both ESR and CRP were significantly associated with CDAI (p &lt; 0.001 for each).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>It is not necessary to obtain both ESR and CRP measures for clinical disease activity assessment in clinical trials of RA. Neither test adds significantly to clinical measures of disease activity including joint counts and global assessments. Where available, the CRP alone may be preferred for disease activity assessment as a simple, validated, reproducible, non age-dependent test.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.081188","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T02:00:51Z","timestamp":1245204051000},"page":"1606-1610","source":"Crossref","is-referenced-by-count":75,"title":["Which Measure of Inflammation to Use? A Comparison of Erythrocyte Sedimentation Rate and C-Reactive Protein Measurements from Randomized Clinical Trials of Golimumab in Rheumatoid Arthritis"],"prefix":"10.3899","volume":"36","author":[{"given":"CYNTHIA S.","family":"CROWSON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAHBOOB U.","family":"RAHMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ERIC L.","family":"MATTESON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2009,6,16]]},"reference":[{"key":"2018112909205131000_36.8.1606.1","first-page":"884","article-title":"Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis","volume":"31","author":"Ward","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909205131000_36.8.1606.2","first-page":"1477","article-title":"Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis","volume":"24","author":"Wolfe","year":"1997","journal-title":"J Rheumatol"},{"key":"2018112909205131000_36.8.1606.3","first-page":"2324","article-title":"Equivalence of the acute phase reactants C-reactive protein, plasma viscosity and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis","volume":"26","author":"Paulus","year":"1999","journal-title":"J Rheumatol"},{"key":"2018112909205131000_36.8.1606.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054205"},{"key":"2018112909205131000_36.8.1606.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330403"},{"key":"2018112909205131000_36.8.1606.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2018112909205131000_36.8.1606.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg072"},{"key":"2018112909205131000_36.8.1606.8","first-page":"100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909205131000_36.8.1606.9","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740"},{"key":"2018112909205131000_36.8.1606.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.23383"},{"key":"2018112909205131000_36.8.1606.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010"},{"key":"2018112909205131000_36.8.1606.12","first-page":"50","article-title":"Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized, double-blind, placebo controlled trial","volume":"67","author":"Smolen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2018112909205131000_36.8.1606.13","doi-asserted-by":"crossref","unstructured":"Emery R Fleischmann RM Moreland LW Golimumab, a human anti-TNF-\u03b1 monoclonal antibody, injected subcutaneously every 4 weeks in MTX-naive patients with active rheumatoid arthritis: 24-week results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009; [in press]","DOI":"10.1002\/art.24638"},{"key":"2018112909205131000_36.8.1606.14","doi-asserted-by":"publisher","DOI":"10.2307\/2286407"},{"key":"2018112909205131000_36.8.1606.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.10.924"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.081188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:28:12Z","timestamp":1543512492000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.081188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,16]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,8,11]]},"published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.3899\/jrheum.081188"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.081188","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,16]]}}}